(MRI), were included in the study. All patients received oral albendazole at a dosage of 30 mglkg for 15 days with a low-dose steroid cover (5-10 mg per day). The patients were followed on day 2, at 2 weeks, 1 month, 3 months, 6 months and 9 months, and finally at 1 year. Orbital sonography was performed at 2 weeks, 3 months, 6 months, 9 months and 1 year. CT scan was performed at 6 months and 1 year.
following death of the cyst. In patients who had received previous treatment with steroids, albendazole treatment was deferred until 1 month after stoppage of the steroids.
Follow-up
Patients were followed on day 2 after starting therapy, at 2 weeks, 1 month, 3 months, 6 months, 9 months and at 1 year. A detailed investigation was performed at each visit. Ultrasonography was repeated at 2 weeks, 3 months, 6 months, 9 months and finally at 1 year. A CT scan was performed at 6 months and 1 year.
Observations
The study included 11 males and 10 females aged 3-40 and an acute orbital cellulitis (Fig. lc) . Many patients had recurrent episodes of acute redness and inflammation.
Thirteen patients were not vegetarians while 8 were vegetarians. Fourteen patients had received at least one course of steroids, 2 of whom were still receiving steroids at the time of presentation. Orbital ultrasonography revealed a well-defined cystic lesion with clear contents and an eccentric hyperechoic area suggestive of a scolex in all the patients (Fig. 2a) . CT or MRI provided additional supportive evidence (Fig. 2b) .
The size of the cysts measured on ultrasonography Ultrasonography revealed a mild obscuration of the cyst wall in places (Fig. 3a) . The scolex was clearly defined in 18 cases. A decrease in the size of the cyst was recorded in 20 cases. Follow-up at 1 month revealed a significant symptomatic improvement in all but one of the patients and a reduction in clinical signs. B-scan sonography now revealed a marked decrease in the size of the cyst and obliteration of the capsule (Fig. 3b) . The scolex could not be detected in 20 patients, whilst in 1 patient a well defined scolex was still present. The following description pertains to the 20 patients who showed a response.
The follow-up visit at 3 months revealed complete resolution of symptoms in all patients except 1, although some patients did complain of diplopia in extreme gaze.
Ultrasonography in these patients now revealed a collapsed cyst with obliteration of the scolex and the clear area. Increased signals were received from the involved muscle, suggestive of inflammation (Fig. 3c) .
Sonographic evaluation at 6 months did not reveal any cysts in the muscle. Areas corresponding to the site of the cysts now revealed increased signal suggestive of infiltration and inflammation (Fig. 3d) . Sonographic follow-up at 9 months revealed only diffuse echoes from the involved muscles which persisted at 1 year (Fig. 3e) .
A CT scan performed in these 20 patients after 1 year Medical management has been tried extensively in cases of neurocysticercosis, but its application to orbital cysticercosis remains to be proven. 5 , 6 Praziquantel and albendazole have been shown to be highly effective in therapy of neurocysticercosis.
Albendazole, a broad spectrum antihelmintic that acts by blocking glucose uptake of the parasite and depleting its glycogen stores, has been reported to have an elimination rate of 80% as compared with 67% for praziquante1. 5
Albendazole has also been shown to be effective in cases not responsive to praziquantel. Response to medical therapy was reported 3 months after initiation of the therapy.
Adverse reactions seen with these drugs are due not to the drug per se but to a strong inflammatory response secondary to the release of toxins following the death of the parasite. Simultaneous use of systemic low-dose corticosteroids and non-steroidal anti-inflammatory agents has been advocated to suppress this response. ethical as preliminary results suggested that the therapy was highly effective. Albendazole was the drug of choice as it has a higher rate of parenchymal cyst removal in neurocysticercosis. We followed a therapeutic regimen of 30 mg/kg body weight for 15 days, together with a low dose of steroid 5-10 mg (depending on the body weight) to suppress the associated inflammatory response.
The results of the study were highly gratifying, showing a cyst elimination rate of up to 95.2%. Our cyst elimination rates are comparable to those reported in a previous series and may be attributed to a high drug availability. 6
Orbital sonography was used as the primary investigation for diagnosis and follow-up as it was cost effective and provided a precise location of the cyst and its surroundings. CT was used to confirm the diagnosis. It is imperative to have a high index of suspicion for the diagnosis of orbital myocysticercosis in patients from endemic areas with subacute proptosis, ocular motility disorders and episodes of inflammation. Oral albendazole therapy seems to be highly efficacious in the management of the condition.
